The randomized, double-blind study will enroll about 150 patients to receive intravenous ALT001 at one of two doses or placebo, with functional change assessed at 24 weeks.
The UMC Utrecht-sponsored, randomized placebo-controlled study plans to enroll 162 infants with MRI-confirmed hypoxic-ischemic brain injury and assess motor development at 24 months.
Regend Therapeutics plans a Phase 3, randomized, blinded, placebo-controlled study enrolling 102 people with COPD and emphysema to assess lung diffusion capacity at 52 weeks.
This Phase I, single-arm study plans to enroll 20 adults with steroid-refractory moderate or severe disease to receive up to three intravenous infusions alongside standard therapy.
Tongji Hospital is recruiting 15 participants for a single-center, dose-escalation Phase 1 study primarily assessing adverse events through 48 weeks after treatment.
Sad day for the industry, here's a summary of the CEO/Executive Chairman's readouts of the trials.
The ASPIRO trial of sasineprocel is progressing; fifteen patients have been dosed with the commercial-ready formulation of the autologous cell therapy.
The Chinese company also received an IND in China a few weeks ago. Supported by good preclinical data, they'll advance clinical trials in both countries soon.
The embryonic-derived cell therapy is implanted directly into the brain, and this early trial hopes to establish safety and baseline efficacy.
This marks the first stem cell therapy for KOA to reach Phase III in China. The race is heating up...
